According to the company, tolimidone significantly reduced HbA1c in comparison to placebo in the mid-stage trial as per the analysis of all patients who were subjected to the
The post Melior’s tolimidone succeeds in phase 2b trial in Type 2 diabetes appeared first on Pharmaceutical Business review.
Original Article: Melior’s tolimidone succeeds in phase 2b trial in Type 2 diabetes